Extended Data Fig. 10: Antitumor effects of anti-PD-1 combined with IMQ on B16-F10 melanoma.
a, Schematic representation of the murine model used to test the antitumor effect of anti-PD-1 therapy and memory formation after combination therapy. To test anti-PD-1 therapy mice were treated with anti-PD-1 antibody (200 µg, i.p.) every other day (3 times). To test memory formation: B16 tumors were surgically resected after five days of consecutive IMQ treatment (topical and oral), and mice were re-challenged at the indicated time-point. b, Tumor growth was monitored in B16-F10 melanoma-bearing mice. Mice were treated with anti-PD-1 antibody (every other day, 3 times), and/or IMQ topically and orally (5 consecutive days). (Vehicle: Ig Control and anti-PD-1 n = 6, IMQ topical &oral: Ig Control and anti-PD-1 n = 5; n is the number of mice from 1 experiment). c, Tumor growth was monitored in B16-mOVA melanoma-bearing mice during Therapy (5 days) and after treatment termination (post-Therapy). Therapy included treatment with anti-PD-1 antibody (every other day, 3 times), and/or IMQ topically and orally (5 consecutive days). In c-e n = 4 mice per group; 1 experiment. d, Frequency of CD8α T cells and of OVA-specific (SIINFEKL) CD8α T was assessed by flow cytometry in tumors described in (c). e, Percentage of Type I and Type II DCs and pDCs was analyzed by flow cytometry in tumors described in (c). Data are shown as mean ± SEM. Dots in d and e represent biological replicates. P‐values were calculated by unpaired, two-tailed t-test (d, e) and two-way ANOVA with Tukey´s post-test (b, c).
